Company intelligence / Profile preview
Versartis, Inc.
Menlo Park, California, United Statesversartis.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Versartis developed a long‐acting form of recombinant human growth hormone using the XTEN technology platform. Its lead candidate, VRS‐317 ("Somavaratan"), aimed to reduce injection frequency for patients with growth hormone deficiency from daily to monthly or semi-monthly dosing. The company advanced this program into late-stage clinical trials but ultimately discontinued development after failing to meet primary endpoints in pivotal studies. Other pipeline assets targeting oncology indications were also discontinued or did not progress beyond early clinical phases.[2][5]
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Recombinant proteins (notably long-acting recombinant human growth hormone)Antibody fusion proteins[3][5]Monoclonal antibodies[3]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Technology license agreement with Amunix for XTEN platform; no major pharma partnerships reported.
Beyond the preview
Go deeper on Versartis, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Versartis, Inc..